Search

Search Results

1. MR-based radiomics predictive modelling of EGFR mutation and HER2 overexpression in metastatic brain adenocarcinoma: a two-centre study

   Objectives

   Magnetic resonance (MR)-based radiomics features of brain metastases are utilised to predict epidermal growth factor receptor (EGFR)...

   Yanran Li, Yong **, ... Jian Wang in Cancer Imaging

   Article Open access 21 May 2024
   

2. Exploring the correlation between HER2 alterations and ¹⁸F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients

   Purpose

   Our study intended to explore the correlation between HER2 alterations and ¹⁸ F-FDG PET/CT metabolic parameters and their prognostic value in...

   Maomei Ruan, Cheng Chang, ... Yuetao Wang in Journal of Cancer Research and Clinical Oncology

   Article 12 August 2023
   

3. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival

   Muscle-invasive bladder cancers (MIBCs) is a group of molecularly heterogonous diseases that could be stratified into subtypes with distinct clinical...

   Duaa S. Helal, Sara A. Darwish, ... Dina M. El-Guindy in Diagnostic Pathology

   Article Open access 03 February 2023
   

4. To Study the Role of PTEN, EGFR and HER2 in Early Glottic Squamous Cell Carcinoma

   Laryngeal carcinoma is the most common site of malignancy in head and neck region worldwide. Surgical options are limited in cases of laryngeal...

   Sachin Goel, Ankur Batra, ... Snigdha Goel in Indian Journal of Otolaryngology and Head & Neck Surgery

   Article 06 January 2023
   

5. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

   Purpose

   Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical...

   Sarina A. Piha-Paul, Chieh Tseng, ... Funda Meric-Bernstam in Cancer Chemotherapy and Pharmacology

   Article Open access 14 June 2023
   

6. Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients

   Background

   Metastatic breast cancer (MBC) is a major health problem worldwide. Some patients improve on tamoxifen and others do not respond to...

   Ibrahim Malash, Osman Mansour, ... Abeer Bahnassy in Journal of the Egyptian National Cancer Institute

   Article Open access 25 July 2022
   

7. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

   Protein tyrosine kinases of the human epidermal growth factor receptor family, including EGFR and HER2, have emerged as important therapeutic targets...

   Alex Friedlaender, Vivek Subbiah, ... Alfredo Addeo in Nature Reviews Clinical Oncology

   Article 24 September 2021
   

8. HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer

   Purpose

   To investigate the role of HER2 positivity in prognosis and unresponsiveness to anti-EGFR therapy for colorectal cancer.

   Methods ...

   Wenbai Huang, Yijiao Chen, ... Jianmin Xu in Journal of Cancer Research and Clinical Oncology

   Article 22 June 2021
   

9. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma

   Background

   EGFR and/or HER2 expression in pancreatic cancers is correlated with poor prognoses. We generated homodimeric (EGFRxEGFR or HER2xHER2) and...

   Alan W Long, Hong Xu, ... Nai-Kong V Cheung in Journal of Hematology & Oncology

   Article Open access 23 April 2024
   

10. HER2-Positive Metastatic Colorectal Cancer

    Targeted treatment strategies are available for human epidermal growth factor receptor 2 (HER2)–positive (amplified and/or overexpressed) metastatic...

    Hannah R. Robinson, Wells A. Messersmith, Robert W. Lentz in Current Treatment Options in Oncology

    Article 28 March 2024
    

11. Antibody–drug conjugates (ADCs) in lung cancer treatment

    ADCs will likely become another important treatment strategy in advanced, pretreated lung cancer where current treatment options are limited. Both...

    Romana E. Wass, David Lang, ... Bernd Lamprecht in memo - Magazine of European Medical Oncology

    Article Open access 06 June 2024

12. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

    Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics combining monoclonal antibodies with a cytotoxic payload via a chemical...

    Maximilian J. Mair, Rupert Bartsch, ... Matthias Preusser in Nature Reviews Clinical Oncology

    Article 21 April 2023
    

13. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

    Numerous inherent and acquired genetic alterations have been demonstrated with resistance to anti-epidermal growth factor receptor (anti-EGFR)...

    G. Wang, Y. He, ... Y. Pan in Clinical and Translational Oncology

    Article 05 October 2019
    

14. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients

    Background

    Accurately predicting the response to neoadjuvant chemotherapy (NAC) in breast cancer patients is crucial for guiding treatment strategies...

    Mijia Wang, Zhendong Wei, ... Haidong Zhao in Diagnostic Pathology

    Article Open access 20 March 2024

15. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers

    Background

    Chemo-immunotherapy (CIT) is the standard of care for advanced non-small cell lung cancer (NSCLC), but the impact of routinely available...

    Marine Marchal, Vincent Leroy, ... Alexis B. Cortot in Targeted Oncology

    Article Open access 03 November 2023
    

16. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study

    Background

    This prospective study aims to investigate the efficacy and safety of pyrotinib (P) combined with 4 cycles of epirubicin and...

    Lu Liu, Mingzhi Zhu, ... Yuanting Gu in World Journal of Surgical Oncology

    Article Open access 19 December 2023
    

17. Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma

    Purpose

    Pancreatic Ductal Adenocarcinoma (PDAC) is the most common type of pancreatic malignancies. It is known for its aggressive nature and high...

    S. M. Adnan Ali, Yumna Adnan, ... Hasnain Ahmed Farooqui in Journal of Cancer Research and Clinical Oncology

    Article 06 September 2022
    

18. The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer

    Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in approximately 15–20% of breast cancer cases. HER2 is a member of the...

    Zaid Sirhan, Anita Thyagarajan, Ravi P. Sahu in Military Medical Research

    Article Open access 13 July 2022
    

19. MUC1 triggers lineage plasticity of Her2 positive mammary tumors

    Aberrant overexpression of mucin 1 (MUC1) and human epidermal growth factor receptor 2 (HER2) are often observed in breast cancer. However, the role...

    Zhi Pang, **nran Dong, ... Lei Huang in Oncogene

    Article 23 April 2022
    

20. Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR

    Non-medical use of ketamine as an adulterant to ecstasy is more prevalent than amphetamine in Taiwan. Ketamine’s effect on immunosuppression might...

    Li-Kuei Chen, Chien-Hung Shih, ... Kuen-Bao Chen in Investigational New Drugs

    Article 09 August 2022